2025 has been a busy year so far in terms of new oncology clinical practice guidelines! We’re expanding upon our popular oncology / ASCO / NCCN guidelines rundown article from January 2025, which was focused primarily on ASCO and NCCN guidelines published in that month. This article will take a look at all of the guidelines in oncology published between January and early May 2025.
The guidelines are organized in a list based on the area of oncology and tumor / cancer types and categories. Links are provided to each, with the exception of the NCCN guidelines, as these require an account in order to access. Rather than linking to each individually in the list below, visit NCCN’s website to log in to your account and see the current list of guidelines.
Now, let’s jump right into the list of guidelines for oncologists in the first part of the year 2025!
Blood Cancers & Hematological Malignancies
- CCO - T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)
- ESMO/EHA - Peripheral T and Natural Killer-Cell Lymphomas
- IBCG - Bladder Preservation Strategies in Muscle-invasive Bladder Cancer
- IMWG - Sequencing Immunotherapy for Treatment of Multiple Myeloma
- SITC - Immunotherapy for the Treatment of Lymphoma
- NCCN - Acute Myeloid Leukemia
- NCCN - B-Cell Lymphomas
- NCCN - Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
- NCCN - Hematopoietic Cell Transplantation
- NCCN - Histiocytic Neoplasms
- NCCN - Hodgkin Lymphoma
- NCCN - Kaposi Sarcoma
- NCCN - Multiple Myeloma
- NCCN - Myelodysplastic Syndromes
- NCCN - Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions
- NCCN - Pediatric Acute Lymphoblastic Leukemia
- NCCN - Pediatric Aggressive Mature B-Cell Lymphomas
- NCCN - Primary Cutaneous Lymphomas
- NCCN - Systemic Light Chain Amyloidosis
- NCCN - Systemic Mastocytosis
- NCCN - Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma
Brain Cancers / Neuro-Oncology & CNS Cancers
- ASCO - Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults
- CNS - Treatment of Adults with Metastatic Brain Tumors
- NCCN - Central Nervous System Cancers
- NCCN - Neuroblastoma
- NCCN - Pediatric Central Nervous System Cancers
Breast Cancers
- ASBRS - Preoperative Management of Patients Treated with Neoadjuvant Systemic Therapy
- ASCO - Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
- NICE - Advanced Breast Cancer: Diagnosis and Treatment
- NICE - Early and Locally Advanced Breast Cancer: Diagnosis and Management
- NCCN - Breast Cancer
- NCCN - Breast Cancer Risk Reduction
- NCCN - Breast Cancer Screening and Diagnosis
Endocrine & Neuroendocrine Cancers
- ASCO - Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
- NCCN - Neuroendocrine and Adrenal Tumors
- NCCN - Thyroid Carcinoma
Gastrointestinal Cancers
- AASLD - Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma
- ASCRS - Management of Appendiceal Neoplasms
- ASTRO - Radiation Therapy for Anal Squamous Cell Carcinoma
- ESMO - Treatment of Locally Advanced Oesophageal and Oesophagogastric Junction Adenocarcinoma and Metastatic Squamous Cell Carcinoma
- ESMO - Diagnosis, Treatment and Follow-up of Hepatocellular Carcinoma
- NCCN - Ampullary Adenocarcinoma
- NCCN - Anal Carcinoma
- NCCN - Biliary Tract Cancers
- NCCN - Colon Cancer
- NCCN - Esophageal and Esophagogastric Junction Cancers
- NCCN - Gastric Cancer
- NCCN - Gastrointestinal Stromal Tumors
- NCCN - Hepatocellular Carcinoma
- NCCN - Rectal Cancer
- NCCN - Small Bowel Adenocarcinoma
Genitourinary Cancers
- ASCO - Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- EAU - Muscle-invasive and Metastatic Bladder Cancer
- EAU - Renal Cell Carcinoma
- EAU - Testicular Cancer
- EAU - Non-muscle-invasive Bladder Cancer
- EAU - Upper Urinary Tract Urothelial Carcinoma
- EAU/EANM/ESRO - Prostate Cancer
- ESMO - Management of Metastatic Pancreatic Cancer
- NCCN - Bladder Cancer
- NCCN - Kidney Cancer
- NCCN - Penile Cancer
- NCCN - Prostate Cancer
- NCCN - Prostate Cancer Early Detection
- NCCN - Testicular Cancer
- NCCN - Wilms Tumor (Nephroblastoma)
Gynecologic Cancers
- ASCO - Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer
- NCCN - Cervical Cancer
- NCCN - Gestational Trophoblastic Neoplasia
- NCCN - Ovarian Cancer Continue Including Fallopian Tube Cancer and Primary Peritoneal Cancer
- NCCN - Uterine Neoplasms
- NCCN - Vaginal Cancer
- NCCN - Vulvar Cancer
Head and Neck Cancers
- ASCO - Transoral Robotic Surgery in the Multidisciplinary Care of Patients with Oropharyngeal Squamous Cell Carcinoma
- CAP - Human Papillomavirus Testing in Head and Neck Carcinomas
- ESMO - Sinonasal Malignancy
- NCCN - Head and Neck Cancers
Lung Cancers / Thoracic Cancers
- ASCO - Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations
- ASCO - Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations
- ASCO - Treatment of Pleural Mesothelioma
- STS - Surgical Management of Oligometastatic Non-small Cell Lung Cancer
- NCCN - Mesothelioma: Peritoneal
- NCCN - Mesothelioma: Pleural
- NCCN - Non-Small Cell Lung Cancer
- NCCN - Small Cell Lung Cancer
Skin Cancers / Sarcomas / Bone Cancers
- SITC - Immunotherapy for the Treatment of Melanoma
- NCCN - Basal Cell Skin Cancer
- NCCN - Bone Cancer
- NCCN - Melanoma: Cutaneous
- NCCN - Melanoma: Uveal
- NCCN - Merkel Cell Carcinoma
- NCCN - Myeloproliferative Neoplasms
- NCCN - Soft Tissue Sarcoma
- NCCN - Squamous Cell Skin Cancer
Supportive Care, Survivorship, and Molecular Testing
- ASCO - Fertility Preservation in People With Cancer
- ASCO - Germline and Somatic Genomic Testing for Metastatic Prostate Cancer
- ASCO/MASCC - Opioid Conversion in Adults with Cancer
- NICE - Suspected Cancer: Recognition and Referral
- NCCN - Adult Cancer Pain
- NCCN - Antiemesis
- NCCN - Cancer-Associated Venous Thromboembolic Disease
- NCCN - Cancer-Related Fatigue
- NCCN - Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate
- NCCN - Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric
- NCCN - Palliative Care
- NCCN - Survivorship
Wow - that is a lot of guidelines for oncologists, and we’re not even half way into 2025 yet!
To help stay on top of things, you can sign up for Guideline Alerts to always learn about new oncology guideline releases, and/or you can also keep your eye on the Oncology section of the guidelines library database as well.
Copyright © 2025 Guideline Central, All Rights Reserved.